Yield10 Bioscience submits letter to USDA-APHIS BRS for C3007
Yield10 Bioscience announced that it has submitted an "Am I Regulated?" letter to USDA-APHIS's Biotechnology Regulatory Services to confirm that the use of CRISPR genome-edited trait C3007 in Camelina sativa plant lines for increased oil content does not meet the definition of a regulated article under 7 CFR Part 340 regulations. Once regulatory status of the plants is confirmed, Yield10 plans to conduct field tests of CRISPR genome-edited Camelina plants in the United States. Yield10 licensed C3007 from the University of Missouri in mid-2018. The protein encoded by C3007, also known as BADC, is a novel, negative regulator of the enzyme acetyl-CoA carboxylase, the key enzyme for producing fatty acids for oil biosynthesis. In pilot studies conducted by MU researchers, reducing activity of the protein encoded by C3007 resulted in significantly increased oil content in seeds. Yield10 researchers have now successfully used CRISPR to reduce the activity of C3007 in Camelina and have seen clear evidence of increased oil content in some lines in laboratory studies. The use of CRISPR may enable an expedited timeline for development and commercialization within the U.S. market based on obtaining confirmation that USDA-APHIS does not consider the lines to be regulated pursuant to 7 CFR part 340. The lines may still be subject to regulation by EPA or FDA.